DSIP
Delta Sleep-Inducing Peptide
Nonapeptide originally isolated from rabbit brain during slow-wave sleep in 1977. Promotes delta slow-wave sleep — the most restorative sleep phase. Studied for circadian rhythm regulation.
Mechanism of action
Modulates GABA-A receptors and reduces beta-adrenergic activity. Promotes delta slow-wave sleep phase specifically rather than causing general sedation. Has analgesic stress-reducing and antioxidant properties in animal models. Effects on corticotropin release also studied.
Effects in the body
DSIP was discovered in 1977 when scientists isolated it from rabbit brain during slow-wave sleep. It specifically promotes the deep restorative delta sleep phase rather than simply sedating. This targeted sleep stage promotion rather than general sedation is what makes it scientifically interesting.
Pros & cons (from the literature)
- Promotes specific delta sleep — most restorative phase
- Non-sedating mechanism — natural sleep pattern enhancement
- Antioxidant and stress-reducing properties in animal models
- Potential for jet lag and circadian rhythm research
- RUO status not compoundable in USA
- Very limited human clinical data
- Half-life very short making dosing complex
- Long-term effects unknown
- Manufacturing and stability challenges
Protocol summary (from published research)
Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.
FDA & regulatory status
Evidence base
1977 discovery paper foundational. Preclinical data mechanistically interesting. Very limited human studies published. Mechanism not fully characterized in humans.
Primary research sources
Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.